News | September 23, 2007

NAS Study Shows Need to Restore Federal Nuclear Medicine Research Funding

September 24, 2007 – The Society for Molecular Imaging and Nuclear Medicine (SNM) recently reported that based on the results of a recent National Academy of Sciences report, federal funding for basic molecular imaging/nuclear medicine research should be restored to the U.S. Department of Energy.

Funded by the Department of Energy and the National Institutes of Health, the 13-month, $700,000 report was prompted by a $23 million cut in funding from the DOE Office of Sciences' fiscal year 2006 budget, which effectively eliminated most money for basic nuclear medicine and molecular imaging research. The DOE has funded basic molecular imaging/nuclear medicine research since biomedical research was initially included in the Atomic Energy Act of 1954. This research has lead to the introduction of many life-saving technologies over the years. "Advancing Nuclear Medicine Through Innovation" recommends that the federal government "enhance" its commitment to nuclear medicine research since "expanded use of nuclear medicine techniques has the potential to accelerate, simplify and reduce the costs of developing and delivering improved health care and could facilitate the implementation of personalized medicine."

"The loss of funding for nuclear medicine research in the U.S. Department of Energy budget has been a tremendous blow to—most importantly—our current and future patients and our field," said SNM President Alexander J. McEwan, who represents 16,000 physicians, technologists and scientists. "This report confirms that funding for this nation's basic research program must be restored or future life-saving diagnostic and treatment procedures could be lost to all Americans," he added.

"If funding is not restored in the 2008 fiscal year, it will be detrimental to researchers and their labs. This is the only federal government research money dedicated to basic nuclear medicine research and there are no plans to move this research to another federal agency," explained Peter S. Conti, chair of SNM's Government Relations Committee. "Our country needs to invest in the basic scientific research necessary to develop future breakthroughs in nuclear medicine imaging and therapy that will allow for earlier detection and treatment of cancer and other serious illnesses," he noted.

Briefly, the NAS report calls for enhanced federal commitment to nuclear medicine research; recommends that regulatory requirements—for toxicology and current good manufacturing practices facilities—be clarified and simplified; notes that domestic medical radionuclide production should be improved and suggests that DOE and NIH convene expert panels to identify critical national needs for training nuclear medicine scientists and encourages interdisciplinary collaboration.

For more information: www.snm.org

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init